AD-FTD Tau-TDP-43 Overlap: Mechanism Comparison

Overview

Alzheimer’s disease (AD) and frontotemporal dementia (FTD) were long viewed as distinct entities — amyloid-beta and tau-driven neurodegeneration versus frontotemporal lobar degeneration (FTLD) characterized by tau or TDP-43 pathology. However, research over the past decade has revealed extensive molecular overlap: TDP-43 proteinopathy is present in approximately 40-57% of AD cases at autopsy, while tau pathology appears in many FTD subtypes, creating a complex landscape of co-pathology that blurs traditional diagnostic boundaries^{1Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis2006 · Science · DOI 10.1126/science.1134108Open reference2TDP-43 is a key driver of primary age-related tauopathy2014 · Brain · PMID 24159144Open reference}.

This page systematically compares the molecular mechanisms of tau and TDP-43 involvement across AD and FTD, examines their distinct and shared spreading mechanisms, delineates clinical phenotypes arising from co-pathology, and explores therapeutic implications of this overlap.

1. Molecular Basis of Tau-TDP-43 Co-Pathology

1.1 TDP-43 in Alzheimer’s Disease

TDP-43 pathology in AD was first formally described as “TDP-43 type A” inclusions in 2006 by Arai et al., who observed that a subset of AD cases harbored TDP-43-positive, tau-negative inclusions in the medial temporal lobe^{3TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis2006 · Biochem Biophys Res Commun · PMID 17023654Open reference}. Subsequent studies by Neumann et al. and others established that TDP-43 inclusions in AD follow a stereotypical pattern: beginning in the hippocampal formation, spreading to the amygdala, and eventually reaching the neocortex in advanced cases^{1Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis2006 · Science · DOI 10.1126/science.1134108Open reference}.

The prevalence of TDP-43 pathology in AD varies by cohort and detection method:

• Approximately 20-30% of clinically diagnosed AD cases show TDP-43 inclusions at autopsy

• Up to 50-57% show TDP-43 pathology when sensitive antibodies are used

• Limbic-predominant TDP-43 in AD correlates strongly with memory impairment beyond what tau alone would predict^{4TDP-43 pathology, Alzheimer type neurodegeneration, and effects on cognition2013 · Brain · PMID 23449259Open reference}

Key molecular features of AD-associated TDP-43:

• Phosphorylation: TDP-43 in AD shows hyperphosphorylation at serine 409/410, similar to FTLD-TDP

• Truncation: C-terminal fragments of TDP-43 are detected in AD brains

• Mislocalization: TDP-43 shifts from nuclear to cytoplasmic compartments

• Upregulation: Total TDP-43 levels are increased in AD cortex, suggesting transcriptional dysregulation^{5Nuclear localization and aggregation of TDP-43 in Alzheimer's disease2017 · Acta Neuropathol · PMID 28417093Open reference}

1.2 Tau Pathology in Frontotemporal Dementia

Tau pathology in FTD is heterogeneous, spanning multiple 3R, 4R, and mixed 3R/4R tauopathies. The FTLD-tau spectrum includes:

• Pick’s disease (3R tau): spherical Pick bodies, frontal/temporal atrophy

• Progressive supranuclear palsy (PSP) (4R tau): globose neurofibrillary tangles, brainstem involvement

• Corticobasal degeneration (CBD) (4R tau): astrocytic plaques, asymmetric cortical atrophy

• FTLD-tau with MAPT mutations: familial forms with pathogenic variants in the MAPT gene

Unlike AD, FTD tau pathology typically:

• Is independent of amyloid-beta deposition

• Shows selective vulnerability of frontal and temporal regions

• May involve specific tau splice isoforms (3R vs 4R dominance)

• Can be driven by genetic mutations in MAPT or other tau-related genes^{6Neuropathology of primary age-related tauopathy and frontotemporal lobar degeneration with TDP-432014 · Acta Neuropathol · PMID 24599760Open reference}

1.3 Primary Age-Related Tauopathy (PART)

PART represents a key intersection between AD and FTD. Josephs et al. (2014) described PART as a distinct entity characterized by:

• Braak stage I-IV tau pathology (neurofibrillary tangles)

• Minimal or no amyloid-beta co-pathology

• TDP-43 co-pathology in up to 80% of cases^{2TDP-43 is a key driver of primary age-related tauopathy2014 · Brain · PMID 24159144Open reference}

PART blurs the line between “pure AD” and “pure FTD-tau,” suggesting a spectrum of age-related tauopathy with variable TDP-43 comorbidity. The high rate of TDP-43 co-pathology in PART has led to the hypothesis that TDP-43 may facilitate tau propagation or vice versa^{7Tau burden in primary age-related tauopathy and cross-disease comparisons2023 · Brain · PMID 38007890Open reference}.

flowchart TD
    subgraph AD_Dominant["AD-Pathology Dominant"]
        A1["Amyloid-beta plaques"] --> A2["NFTs (3R+4R tau)"]
        A2 --> A3["TDP-43 inclusions (40-57%)"]
        A3 --> A4["Limbic-predominant spread"]
    end

    subgraph PART_Overlap["PART / Age-Related Tau"]
        B1["NFTs (3R+4R tau)"] --> B2["Minimal amyloid-beta"]
        B2 --> B3["TDP-43 co-pathology (up to 80%)"]
        B3 --> B4["Hippocampal and limbic"]
    end

    subgraph FTD_Dominant["FTD-Pathology Dominant"]
        C1["MAPT mutations / 3R or 4R tau"] --> C2["FTLD-tau"]
        C1 --> C3["FTLD-TDP-43 (GRN, C9orf72, VCP)"]
        C2 --> C4["Frontal / temporal predominant"]
        C3 --> C4
    end

    A4 -.-> B3
    B4 -.-> C4
    style A1 fill:#bbf,stroke:#333,stroke-width:2px
    style C3 fill:#1a0a1f,stroke:#333,stroke-width:2px
    style B3 fill:#3a3000,stroke:#333,stroke-width:2px

1.4 APOE and Genetic Modifiers

The APOE gene strongly influences tau-TDP-43 co-pathology patterns in AD:

• APOE epsilon 4 (APOE4): Associated with increased amyloid-beta deposition and more extensive TDP-43 pathology. APOE4 carriers with AD show higher rates of TDP-43 co-pathology than non-carriers^{8APOE4 exacerbates TDP-43 pathology and promotes cognitive decline in Alzheimer's disease2024 · J Clin Invest}

• APOE epsilon 2 (APOE2): May be protective against amyloid-beta but does not prevent TDP-43 accumulation

• ABCA7: Genetic variants near ABCA7 are associated with increased AD risk and may influence TDP-43 pathology indirectly^{2TDP-43 is a key driver of primary age-related tauopathy2014 · Brain · PMID 24159144Open reference}0^{2TDP-43 is a key driver of primary age-related tauopathy2014 · Brain · PMID 24159144Open reference}1

In FTD, genetic modifiers include:

• TMEM106B: Common variant (rs3173615) influences TDP-43 pathology burden in FTLD-TDP, particularly in C9orf72 expansion carriers

• GRN and C9orf72: Mutations directly cause TDP-43 proteinopathy in familial FTD

• MAPT: H1/H2 haplotypes and specific mutations drive tau pathology

2. AD vs FTD Pathological Signatures

2.1 Tau Pathology Signatures

2.2 TDP-43 Pathology Signatures

2.3 LATE-NC: Limbic-Predominant Age-Related TDP-43 Encephalopathy

LATE-NC was formalized as a distinct neuropathological change in 2019, representing:

• TDP-43 proteinopathy confined predominantly to limbic structures

• Amnesia-predominant clinical syndrome

• Often co-exists with AD neuropathology^{2TDP-43 is a key driver of primary age-related tauopathy2014 · Brain · PMID 24159144Open reference}2^{2TDP-43 is a key driver of primary age-related tauopathy2014 · Brain · PMID 24159144Open reference}3

LATE-NC is distinct from FTLD-TDP in that:

• It primarily affects older individuals (>80 years)

• The neuroanatomical distribution is limbic-predominant

• It is frequently comorbid with AD neuropathology

• It may represent the third most common dementia pathology after amyloid and tau

The presence of LATE-NC in AD cases significantly worsens cognitive outcomes, with patients showing faster decline and earlier death compared to those with pure AD pathology^{2TDP-43 is a key driver of primary age-related tauopathy2014 · Brain · PMID 24159144Open reference}4.

3. Spreading Mechanisms: Prion-Like Tau vs TDP-43 Granules

3.1 Tau Propagation (Prion-Like)

Tau propagation in both AD and FTD follows prion-like principles^{2TDP-43 is a key driver of primary age-related tauopathy2014 · Brain · PMID 24159144Open reference}5:

Template-driven misfolding: Pathological tau recruits native tau molecules, converting them into the same conformer. This creates “tau strains” that are disease-specific and maintain their identity during propagation^{2TDP-43 is a key driver of primary age-related tauopathy2014 · Brain · PMID 24159144Open reference}6^{2TDP-43 is a key driver of primary age-related tauopathy2014 · Brain · PMID 24159144Open reference}7.

Cell-to-cell spread: Multiple mechanisms facilitate intercellular tau transfer:

• Synaptic vesicle release: Tau is released at presynaptic terminals in activity-dependent manner

• Extracellular vesicles / exosomes: Particularly important in PSP and AD

• Direct cell-to-cell contact: Tunneling nanotubes transfer tau between neurons

• Fluid-phase uptake: Extracellular tau can be taken up by bulk endocytosis

Vulnerability factors:

• Neuronal activity increases tau release

• Neuroinflammation enhances microglial uptake and spread

• Aging reduces chaperone-mediated clearance, increasing extracellular tau accumulation

3.2 TDP-43 Propagation: Phase Separation and Granule Dynamics

TDP-43 spreading differs mechanistically from tau in several key ways^{2TDP-43 is a key driver of primary age-related tauopathy2014 · Brain · PMID 24159144Open reference}8:

Phase separation and granule formation: Under cellular stress, TDP-43 undergoes liquid-liquid phase separation (LLPS), forming stress granules and other membrane-less organelles. This is a physiological response to stress, but in disease states:

• Persistent stress granules become pathological

• TDP-43 within granules can undergo further aggregation

• Liquid-to-solid transitions create seeding-competent species

Distinct from classical prion propagation: Unlike tau, TDP-43 pathology in FTD is not thought to spread via classic templated misfolding in most cases. Instead:

• Gain-of-function: Accumulation of TDP-43 aggregates disrupts normal nuclear and cytoplasmic functions

• Loss-of-function: Sequestration of functional TDP-43 impairs RNA processing

• Stress granule dynamics: TDP-43 pathology propagates through stress granule biology rather than prion templating

Mechanistic differences summary:

flowchart LR
    subgraph tau_spread["Tau Spreading"]
        T1["Misfolded tau"] --> T2["Prion-like templating"]
        T2 --> T3["Intercellular transfer<br/>(exosomes, synaptic)"]
        T3 --> T4["Strain propagation"]
        T4 --> T5["Conformational fidelity<br/>maintained across passages"]
    end

    subgraph tdp_spread["TDP-43 Spreading"]
        D1["Cellular stress"] --> D2["Phase separation<br/>(LLPS)"]
        D2 --> D3["Stress granule formation"]
        D3 --> D4["Liquid-to-solid transition"]
        D4 --> D5["Aggregate accumulation<br/>(no classical templating)"]
    end

    style T1 fill:#bbf,stroke:#333
    style D1 fill:#1a0a1f,stroke:#333

3.3 Cross-Seeding Between Tau and TDP-43

Evidence for direct cross-seeding is limited but emerging:

• In vitro: TDP-43 fibrils can co-aggregate with tau under specific conditions, but templating is weak

• In vivo: Co-pathology of tau and TDP-43 is extremely common, but whether one directly seeds the other remains debated

• Hypothesis: Rather than direct cross-seeding, both proteins may be independently driven to aggregate by shared upstream stressors (e.g., oxidative stress, autophagy impairment, nuclear pore dysfunction)

4. Clinical Overlap: When AD Meets FTD Phenotypes

4.1 AD Patients with FTD-Like Features

Patients with AD can present with FTD-like clinical phenotypes due to:

• Frontotemporal variant AD: Aβ pathology predominantly affecting frontal regions, producing executive dysfunction and behavioral changes reminiscent of bvFTD

• Posterior cortical atrophy (PCA): Typically AD pathology with visuospatial deficits, but can overlap with the logopenic variant of primary progressive aphasia (lvPPA)

• TDP-43 co-pathology: The presence of TDP-43 in AD accelerates memory decline but may also introduce non-amnestic features

4.2 FTD Patients with AD-Like Features

Conversely, FTD patients may present with AD-like syndromes:

• AD phenocopy: Some FTLD-tau cases present with progressive memory loss mimicking AD, particularly in older patients

• PART with TDP-43: Older FTD patients with PART pathology often show memory-predominant phenotypes

• Semantic variant PPA (svPPA): Can be mistaken for AD memory loss if language features are not carefully assessed

4.3 Specific Clinical Syndromes at the AD-FTD Interface

Logopenic variant PPA (lvPPA):

• Initially linked to AD pathology (left posterior temporal-parietal atrophy)

• Now recognized to frequently involve TDP-43 pathology

• Represents a clinical syndrome where AD and FTD features intersect

• Speech apraxia and anomia predominate; often progresses to generalized cognitive decline

Behavioral variant FTD (bvFTD):

• Typically FTLD-tau or FTLD-TDP

• Can be mimicked by frontal-variant AD

• Approximately 20-30% of clinically diagnosed bvFTD patients have AD pathology at autopsy

Semantic variant PPA (svPPA):

• Predominantly FTLD-tau (Pick’s disease) or FTLD-TDP type C

• Loss of word and object knowledge

• AD pathology is uncommon unless amyloid co-pathology is present

4.4 Diagnostic Challenges

flowchart TD
    A["Patient presents with cognitive decline"] --> B{"Core amnestic<br/>deficit?"}
    B -->|"Yes"| C["AD suspected<br/>(but could be LATE-NC)"]
    B -->|"No"| D{"Primary behavioral<br/>or language deficit?"}
    D -->|"Behavioral"| E["bvFTD suspected<br/>(but could be frontal AD)"]
    D -->|"Language"| F{"Which aphasia<br/>variant?"}
    F -->|"Non-fluent"| G["nfvPPA: FTLD-tau likely<br/>(but 10-20% AD)"]
    F -->|"Logopenic"| H["lvPPA: AD or TDP-43<br/>ambiguous"]
    F -->|"Semantic"| I["svPPA: FTLD-tau/TDP likely<br/>(rarely AD)"]

    C --> J["Test for amyloid<br/>(PET CSF)"]
    E --> J
    H --> K["Test for tau<br/>(CSF p-tau217, PET)"]
    G --> K
    I --> L["Test for TDP-43<br/>(CSF NfL, genetic panel)"]

    J --> M["Biomarker integration<br/>for diagnosis"]
    K --> M
    L --> M

5. Therapeutic Implications

5.1 Therapeutic Approaches for Tau-TDP-43 Co-Pathology

The overlap between AD and FTD creates both challenges and opportunities for therapy development^{2TDP-43 is a key driver of primary age-related tauopathy2014 · Brain · PMID 24159144Open reference}9:

Anti-tau therapies (potentially relevant for both AD and FTD-tau):

• Immunotherapies: Aducanumab, lecanemab target amyloid-beta but also reduce tau pathology indirectly; active tau immunotherapies (gosuranemab, semorinemab) have been tested in PSP with limited success

• Small molecule tau aggregation inhibitors: Methylene blue derivatives, BBSwitch, etc.

• Gene therapy: ASO targeting MAPT mRNA (e.g.,IONP-PD) under investigation for PSP and FTD

• Proteolysis targeting chimeras (PROTACs): Tau-targeting degraders in pre-clinical development

Anti-TDP-43 therapies (primarily relevant for FTD and AD-TDP):

• ASOs targeting TDP-43 mRNA: Under investigation in ALS and FTD to reduce TDP-43 expression

• Nuclear import modulators: Enhancing nuclear import of TDP-43 to prevent cytoplasmic aggregation

• Stress granule disruptors: Preventing liquid-to-solid transition of TDP-43 condensates

• Autophagy enhancers: Promoting clearance of TDP-43 aggregates via the autophagy-lysosome pathway

5.2 Shared Upstream Targets

Both tau and TDP-43 aggregation respond to shared upstream stressors, suggesting common therapeutic targets:

5.3 Clinical Trial Considerations

For trials targeting AD-FTD overlap syndromes:

• Patient stratification: Biomarker-based stratification is essential — patients with TDP-43 co-pathology may respond differently to anti-tau therapies

• Endpoint selection: Cognitive endpoints may be confounded by co-pathology; fluid biomarkers (p-tau217, NfL, neurogranin) may be more specific

• Genetic considerations: APOE4 carriers with AD show higher TDP-43 burden and may need separate dosing/treatment arms

• Combination therapy: Given the dual pathology, combination approaches targeting both tau and TDP-43 may be most effective

6. Comparison Matrix: AD vs FTD Tau-TDP Overlap

7. Conclusion

The overlap between AD and FTD at the molecular level reveals that these traditionally separated diseases share more than previously appreciated. TDP-43 pathology is present in a substantial minority of AD cases and accelerates cognitive decline, while tau pathology is a feature of many FTD subtypes. The emergence of PART and LATE-NC as distinct entities further emphasizes that the neuropathological landscape of late-life dementia is a continuum rather than discrete categories.

Understanding the mechanistic intersection of tau and TDP-43 across AD and FTD has several practical implications:

1. Better diagnostic accuracy: Biomarker-based stratification can identify co-pathology and guide treatment

2. Improved clinical trial design: Stratification by proteinopathy burden will reduce heterogeneity

3. Rational therapeutic combinations: Targeting both tau and TDP-43 may be necessary for maximum efficacy

4. Improved prognostic counseling: Patients with dual pathology have different disease trajectories

The dense cross-linking between tau and TDP-43 biology across AD and FTD makes a compelling case for integrated therapeutic strategies that address both proteinopathies, particularly in the aging population where co-pathology is the norm rather than the exception.

See Also

• Frontotemporal Dementia — Disease overview

• TDP-43 Proteinopathy — General TDP-43 mechanism page

• FTD-TDP Pathology — FTD-specific TDP-43 mechanisms

• Tau Pathology in AD — AD tau mechanisms

• Tauopathies Comparison Matrix — Cross-tauopathy comparison

• AD vs PD Neuroinflammation — Cross-disease neuroinflammation

• Primary Age-Related Tauopathy — PART mechanisms

• TDP-43 Phase Separation Pathway — TDP-43 granule biology

• ALS-FTD Spectrum — Overlap between ALS and FTD